T-cell receptor-CD3 complex and T-cell-specific surface glycoprotein CD28 (CD3/CD28)

The CD3/CD28 costimulatory complex is a critical signaling unit on the surface of T cells that governs the initiation and magnitude of the adaptive immune response [nih.gov, mdpi.com]. It comprises the T-cell receptor (TCR) associated with the CD3 signaling subunits (providing 'Signal 1') and the CD28 homodimeric receptor (providing 'Signal 2') [nih.gov]. In a physiological context, this complex is engaged by dendritic cells: the TCR/CD3 complex recognizes peptide-MHC molecules, while CD28 binds to costimulatory ligands CD80 (B7-1) and CD86 (B7-2) [nih.gov, wikipedia.org]. Simultaneous engagement of both pathways is required for robust T-cell activation, leading to clonal expansion, enhanced survival, and high-level production of cytokines such as interleukin-2 (IL-2) [nih.gov, ashpublications.org]. Without the CD28 signal, TCR engagement typically results in T-cell anergy or tolerance [nih.gov]. This complex is a central pillar of modern immunotherapy; agonists like bispecific T-cell engagers (BiTEs) and CAR-T cells leverage these signals to eradicate tumors, while antagonists and ligand-blocking agents like abatacept are used to suppress unwanted immune responses in autoimmunity and organ transplantation [nih.gov, medchemexpress.com].

Other names

CD3/CD28 costimulatory complexTCR/CD3-CD28 complexT-cell activation complexSignal 1 and Signal 2 complexCD3-CD28 costimulatory unit

Drugs targeting this complex act through several mechanisms: costimulation blockade prevents the CD28-B7 interaction to suppress T-cell activation; CD3-directed antibodies modulate TCR signaling; bispecific T-cell engagers bridge T cells to tumor cells via CD3; and chimeric antigen receptors (CARs) incorporate CD3-zeta and CD28 signaling domains to drive potent anti-tumor responses.